Everything you know about toxic shock syndrome is probably wrong

https://goo.gl/5cFsN4

First off, it’s not just a tampon thing.

TSS is back in the news because a model — who lost her leg to the disease in 2012 — is on an awareness campaign to teach young girls about the dangers of tamponsHer story is horrifying, and is only more depressing now that she may have to have a second leg amputated. It seems all the scarier when you realize that she hadn’t even left the offending tampon in for very long (in fact, based on her telling of it, she felt ill before she put one in).

Every woman I know heard these tales as a kid and had one takeaway: we were all definitely going to get TSS if we left a tampon in for even a minute longer than the prescribed eight hours. In 9th grade I accidentally left one in for 12 hours and genuinely thought I’d narrowly escaped death. But it turns out almost everything that I and other girls my age believed about TSS is flat-out wrong. Let’s clear up a few misconceptions, starting with the basics.

Could you remind me ahem, my friend what TSS actually is?

Don’t be embarrassed. I would venture a guess that most folks don’t really know what TSS is, besides “a horrifying disease that you get from tampons.”

Toxic shock syndrome isn’t really a disease in and of itself. It’s a complication of a bacterial infection. There are two kinds of bacteria, staphylococcus aureus and group A streptococcus, that can produce a toxin called TSST-1 (toxic shock syndrome toxin 1). TSST-1 is a superantigen, which means it prompts the immune system to massively overreact to an infection. The resulting storm of immune cells causes the body to go into shock as inflammation spreads and a fever rises, and if left unchecked will eventually cause multi-organ failure. And the toxin can enter the bloodstream even if the bacteria are isolated to one area, so an infection in a single part of the body can end up killing you. Other toxins can also cause TSS, but TSST-1 is the most common one for tampon-related cases.

TSS is actually really rare

In 2016, the CDC reported a grand total of 323 cases. That’s not insignificant, but is pretty tiny when you consider that there are roughly 63 million women between the ages of 15 and 44 in the United States. That’s a rate of 0.0005 percent. Even fewer people died of it that year — just 26 men and women. This isn’t to minimize those losses, because for the victims and their families, TSS was devastating. But on the spectrum of possible causes of death to worry about, toxic shock syndrome is exceedingly unlikely.

And for all you youths out there who are terrified to leave a tampon in for more than a few hours, rest assured that millions of adults regularly fail to remove tampons in a timely fashion. It’s generally not a problem, and TSS doesn’t often have much to do with tampons anyhow.

A third of all TSS cases happen in men

That’s right — men. Do you know who is arguably the most famous person to die from TSS? Jim Henson, the creator of The Muppets.

Toxic shock syndrome isn’t unique to tampon use, it’s just more common in the tampon-using population. Less than half of all cases involve a tampon, however. The rest of the women have an infected wound of some kind, like a surgical incision from a c-section.


Regular Aspirin Use May Slow COPD Progression

This is startlingly good news.....

https://goo.gl/hzVVSH

Analysis showed 50% reduction in emphysema progression.

Regular aspirin use was associated with a more than 50% reduction in emphysema/chronic obstructive pulmonary disease (COPD) progression in an elderly cohort over a decade in a longitudinal analysis of data from a large lung study.

The association was seen across aspirin doses and was greatest in older study participants with significant airflow obstruction.

Results were similar in ever-smokers and for doses of 81 mg and 300-325 mg. A greater magnitude effect was seen among participants with airflow limitations.


Antidepressant May Help Combat the Course of Multiple Sclerosis

https://goo.gl/SkNcct

The antidepressant clomipramine may also alleviate symptoms of multiple sclerosis (MS), specifically in its progressive form, i.e. when it occurs without relapses or remissions. As yet, drugs for this type of MS have been virtually non-existent. Researchers collaborating with Prof V. Wee Yong, PhD, from the University of Calgary and Dr Simon Faissner from Ruhr-Universität Bochum screened 1,040 generic therapeutics and, based on preclinical studies, identified one that is suitable for the treatment of multiple sclerosis. They published their results in the journal Nature Communications from December 19, 2017.

Today, twelve drugs have been approved for the treatment of relapsing-remitting multiple sclerosis; for the progressive types, on the other hand, only a few therapy approaches exist. “The mechanisms causing damage in progressive MS are not always the same as in relapsing-remitting MS. This is why the latter requires different therapeutic approaches,” says Simon Faissner. As postdoctoral researcher of the Department of Neurology at St Josef-Hospital in Bochum, he contributed to a study carried out at the Cumming School of Medicine, University of Calgary as a visiting scholar, funded by the grant for medical research awarded by the Ruhr-Universität’s Faculty of Medicine.

Potential side effects already well-documented

The team worked with approved drugs, the side effects of which have already been amply documented. From among those drugs, the researchers selected 249 well-tolerated therapeutics that enter the nervous system safely; this is where chronic inflammation occurs in progressive MS. Using cell cultures, they tested which of the 249 substances are capable of protecting nerve cells from the damaging influence of iron. In MS patients, iron is released due to cell damage, damaging nerve cells in turn.

Following those tests, 35 potential candidates were identified; the researchers subsequently analysed them with regard to additional properties: investigating, for example, if they can reduce damage to mitochondria – the powerhouses of the cells – or if they minimise the activity of leucocytes that attack the insulation of nerve cells in MS patients. In the process, the drug clomipramine proved promising.

Positive results in preclinical studies

In the next step, the researchers analysed the substance in mice suffering from a disease comparable with relapsing-remitting multiple sclerosis in humans. The therapy suppressed the neurological disturbances completely; as a result, damages to the nerve cells and inflammation were minimised.

In a subsequent test, they treated mice with a disease that resembles progressive MS in humans. Here, too, the therapy proved effective, provided the researchers applied it immediately after the first clinical symptoms became apparent. Symptoms such as paralysis were thus reduced – unlike in control animals that were treated with placebo drugs.


Patients Legally Using Cannabis Stopped Or Used Less Opioids & Dangerous Prescription Drugs

https://goo.gl/ybRTvQ

Our elected officials and health care providers may hope to curb the opioid epidemic through traditional addiction recovery programs and criminalization, but it’s time for them to consider the potential that medical cannabis has to offer in this effort.

All year, researchers from all over the country have been publishing concrete evidence proving that the legalization of medical marijuana leads to happier, healthier patients. Another study, released this week, has found that patients are replacing their prescription drugs with medical marijuana.

Published in the Journal of the American Medical Directors Association, the study concluded that chronic pain sufferers who were legally able to use medical cannabis eventually ended up using fewer opioids and other dangerous prescription drugs.

By the 10-month mark of being enrolled in the New Mexico Medical Cannabis Program (MCP), patients with chronic back pain, arthritis, chronic headaches, fibromyalgia, and other chronic musculoskeletal conditions significantly reduced their prescription drug use. Over a third of the patients enrolled in the MCP stopped using prescription drugs altogether, compared to only two percent of the non-enrolled participants.


Booming Boise Picks a Fight With CVS

https://goo.gl/21q6F2

CVS Health, the largest retail pharmacy chain in America, announced early this month that it planned to purchase Aetna, one of the largest health insurance companies. It was a move analysts say was meant to keep the brick-and-mortar pharmacy juggernaut competitive as e-tailer Amazon moves in to disrupt the prescription drug industry.

Over the last few years, CVS has become all-but-synonymous with “drug store” for much of the U.S., wiping out independent pharmacists as its outlets have marched through cities coast-to-coast. CVS has been on a tear during the last decade, with stores in 49 states, Washington, D.C., Puerto Rico, and Brazil. The number of CVS storesgrew more than 30 percent to more than 9,700 from 2012 to 2017. More than 1,600 are located inside Target stores, which in 2015 sold its pharmacies to CVS for $1.9 billion.

The state of Idaho, however, has only two lonely CVS outposts. Both are inside Targets, and neither is in Boise, the fast-growing high-desert capital city of 223,000. The company has been trying to remedy that situation: In October, a developer filed an application to build a single-floor 12,000-square-foot CVS retail pharmacy on Boise’s West State Street, an urban gateway that links multiple neighborhoods to the city’s downtown.

To make space for the store and its parking lot—which would have occupied nearly a city block—the developer planned to demolish three homes and a building with 23 low-income residences, at a time when the city’s downtown is quickly gentrifying and concerns about low-income residents being pushed out are intensifying.

But CVS ran into a chorus of community opposition, triggering a land-use battle that pits the pharmacy chain against a cadre of spirited smart-growth advocates who say that the drug goliath threatens the town’s essential character. Boise has been welcoming an influx of new residents lately—many from high-cost cities in California and the Pacific Northwest—drawn by the relatively inexpensive housing and laid-back outdoorsy vibe. (Boise’s local ski hill, Bogus Basin, is a nonprofit.) Longtime Boise residents don’t want the development that’s coming along with these newcomers to turn Boise into a city indistinguishable from the places they left.


Net neutrality repeal may diminish telemedicine access, harm small practices

https://goo.gl/aEhHrc

“If I can do that, that would be a very healing experience,” he said. “Well, repealing net neutrality may screw that up. They may charge those patients a zillion dollars for the necessary bandwidth I need to communicate and to do my job better.”

Cyber protection, competition

Another hurdle to telemedicine if net neutrality is repealed involves encryption. Everything that is transmitted through telemedicine portals has tomust be encrypted to meet HIPAA laws.

“Say an ISP decides they no longer want encrypted traffic to go across their network because they want visibility into everything that goes across their line. At that point we’re just hoping that they’re going to continue to pass that traffic,” Greg Hall, IT director for the Center for Telehealth at the University of Mississippi Medical Center, told Healio.com. “If they decide they don't want to or want us to pay them additional fees to have the traffic that is encrypted then suddenly we’re stuck. They could very easily block it all and we can no longer do a telehealth encounter because we can’t pass our traffic over our networks. Our business is completely stopped because one ISP somewhere on the chain has decided that they don't like that kind of traffic.”

Even if major ISP providers such as AT&T, Verizon and Sprint continue to operate under the guidelines of net neutrality and do not restrict access, there still could be hurdles to telemedicine, Hall said.

“You have a small rural ISP that decides, ‘Hey, no we don’t want to play all those games, we want to charge a certain fee for certain traffic’ and say that happens to be the video traffic that we push across the internet at some point. All of the sudden, that small little provider, just because we happen to pass some traffic across their network, could very easily cripple access at that point.

“The main concern is not even just, ‘Hey, our bill comes from AT&T every month.’ It doesn't always just go over AT&T lines, so we have to worry about every ISP that our traffic happens to go across to get from one location to another.”

And although major ISPs might say there will be no changes, Hall said there are examples where that has not been the case. Previously, he said, larger providers blocked video applications from going across their network because they competed with another service the provider already offered.


A Milestone for CAR T Cells

https://goo.gl/H4bHcW

More than 7 years have passed since the regression of advanced lymphoma was first reported in a patient who had undergone the infusion of T cells engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen expressed on the surface of both normal and malignant B cells.1Subsequent trials of CD19-targeted CAR T-cell therapy showed a complete response in some patients with relapsed or chemotherapy-refractory hematologic cancers for which there were no effective therapies.2-5

The recent approval of anti-CD19 CAR T-cell therapy for the treatment of relapsed or refractory acute lymphoblastic leukemia and large B-cell lymphomas by the Food and Drug Administration sets a new standard of care for the patients who receive these therapies. However, the approval also comes with substantial economic challenges because of the high cost of care, a challenge that will grow as the indications for these therapies expand in the future. Policies will need to be developed to ensure that eligible patients receive these potentially curative therapies.


Groundbreaking New Drug Successfully Suppresses Huntington's Protein In Human Trial

https://goo.gl/SYhiXT

In what is thought to be one of the biggest breakthroughs in the treatment of neurodegenerative diseases in the last 50 years, researchers have created a drug that may one day slow the progression of Huntington's disease

A tragic neurodegenerative disease, Huntington's is caused in most people by a single genetic mutation, although a small number of others do develop the genetic fault through random mutation. The gene in question codes for a protein known as huntingtin that builds up in the brain, causing the progressive degeneration of the nervous system and significantly harming movement, learning, thinking, and emotions.

The new drug is designed to disrupt the expression of this faulty gene, preventing the production of huntingtin and thus hopefully slowing the onset of the disease.

Known as IONIS-HTTRx, the drug does not target the gene itself, but is instead a piece of synthesized genetic code that binds to the piece of messenger RNA that transports the information needed to build huntingtin around the cell. By doing this, the drug destroys the messenger molecule before the damaged proteins form. The researchers were able to dramatically cut the levels of this protein found in the brain.

It is important to stress that the trials carried out so far were not looking at whether or not the new treatment prevented the symptoms of the disease from progressing, so the researchers cannot say unequivocally that it works. Instead, they were looking at the level of the toxic protein found in the nervous system.

They found that the level of the toxic protein in the brain was linked to the dose of the medicine, suggesting that the new drug does indeed target the manufacturing of the protein as expected. This is coupled with the fact that the drug had no adverse effects and was seemingly safe.


Traveling With Chronic Pain? Tips From a Spoonie

https://goo.gl/koSg4W

Last January, I had a terrible flare of what I soon learned was psoriatic arthritis. I had to learn how to travel across the country by myself with an uncontrolled autoimmune disorder. I had to adjust my daily life to being a spoonie. (“Spoons” are finite units of measurement that those of us with chronic illnesses use to budget our energy throughout the day – more explanation here.)  But how could I adjust my travel plans?

Airports Are Big. Flights Are Long. Plan Ahead.

• Purchase your tickets well in advance so you can select your seat – and buy as much comfort as you can afford. Take Business class if you can swing it. If you’re in economy, try to get a seat with extra leg room. And take the window seat. If I can avoid basic economy center seats for the rest of my life, I will.

• Get to the airport early and check your luggage. Even if it’s a carry-on size roller-bag. When I fly by myself, I only carry on the backpack that I can put under the seat in front of me. Managing extra luggage just means additional pain for my hands and wrists.

• Use a wheelchair. When I asked for travel tips, one of the things my friends and family repeatedly advised was “swallow your pride.” I have a hard time with this. I want to muscle through. But, even in small airports, I find it’s a mistake to think I can muscle through and go without a wheelchair. (And even if I can, I’ve then spent a spoon or two that I might want to save for after I land at my destination!)

You can reserve a free wheelchair service when you buy your ticket. But whether you reserved it ahead of time or not, when you arrive at the ticketing counter to check that luggage, let the agent know that you need a wheelchair. Usually, someone wheels a chair out for me to sit in while they dispatch a “pusher” out to me. Again, planning well in advance is necessary, because this can take a while if it’s a smaller airline and has a shared pool of wheelchair attendants. The service is always free, but it is customary to tip your wheelchair attendants. They are so nice and friendly, it’s hard not to overflow with gratitude.

The wheelchair attendant will scan your boarding pass – this is very important, because for some airlines, that’s the only way to ensure you’ll have one waiting on the ramp upon arrival at your destination. (Yes, you added it to your ticket when you bought it, but that doesn’t guarantee someone will be waiting. Also, just because you added it to your ticket doesn’t mean anyone will notice until you say something at check-in.)


CVS is buying Aetna in massive deal that could transform health care

https://goo.gl/nmu9kJ

If approved, the $69 billion acquisition -- $77 billion including debt -- would drastically remap the healthcare industry. CVS Health (CVS)is a massive drugstore chain and prescription drug insurer, while Aetna (AET) is one of the nation's largest health insurers.

It would also go down as the largest health insurance deal in history, far exceeding Express Scripts (ESRX)' $29 billion acquisition of Medco in 2012, the last record-holder.

The acquisition is not a done deal. It will have to be approved by antitrust regulators, who have been skeptical of similar health care mergers.

Buying Aetna puts CVS in a better position to compete with other integrated health care providers, such as UnitedHealthcare (UNH) and pharmacy benefits manager Optum. PBMs like Optum and CVS's Caremark help manage prescription drug plans for commercial health insurers.